Results 161 to 170 of about 623 (213)

Angiopoietin‐like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride‐rich lipoproteins in humans

Journal of Internal Medicine, Volume 300, Issue 3, Page 312-328, September 2026.
Abstract Background Angiopoietin‐like protein 3 (ANGPTL3) is a key circulating regulator of triglyceride metabolism and a promising pharmacological target. The physiological consequences of profound ANGPTL3 deficiency can be explored in individuals with inherited loss‐of‐function (LOF) variants, who show reduced lifetime risk of atherosclerotic ...
Marcello Arca, Elias Björnson, Laura D'Erasmo, Alessia Di Costanzo, Simone Bini, Ilenia Minicocci, Daniele Tramontano, Stella Covino, Giuseppe Ciarlo, Manuela Lombardi, Sanni Söderlund, Niina Matikainen, Linda Andersson, Martin Adiels, Marja‐Riitta Taskinen, Chris J. Packard, Jan Borén   +16 more
wiley   +1 more source

Anti‐inflammatory agents in atherosclerosis—and a need for reform: Extraordinary claims require extraordinary evidence

Journal of Internal Medicine, Volume 300, Issue 3, Page 258-283, September 2026.
Abstract Since 1858, human atherosclerotic plaques have been shown to contain immune cells. But are these cells suitable therapeutic targets? Dozens of clinical trials of anti‐inflammatory agents other than colchicine have been performed in patients with clinically evident atherosclerosis.
Kevin Jon Williams
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Decreased Production and Increased Catabolism of Apolipoprotein B-100 in Apolipoprotein B-67/B-100 Heterozygotes

Arteriosclerosis, Thrombosis, and Vascular Biology, 1997
Abstract Apolipoprotein (apo) B-67 is a truncated form of apoB-100 due to deletion of an adenine at cDNA 9327. Heterozygotes have one allele making apoB-100; therefore, plasma apoB levels would be predicted to be at least 50% of normal. However, apoB-67 heterozygotes have total plasma apoB levels that are 24% of normal.
F K, Welty, A H, Lichtenstein, P H, Barrett, G G, Dolnikowski, J M, Ordovas, E J, Schaefer   +5 more
openaire   +2 more sources

Reduction of Lipid Hydroperoxides by Apolipoprotein B-100

Biochemical and Biophysical Research Communications, 1999
We have previously isolated two proteins which can reduce phosphatidylcholine hydroperoxide (PC-OOH) from human blood plasma and identified one of the proteins as apolipoprotein A-I (Mashima, R. , et al. (1998) J. Lipid Res. 39, 1133-1140). In the present study we have identified the other protein as apolipoprotein B-100 (apo B-100) by amino acid ...
R, Mashima, S, Yoshimura, Y, Yamamoto
openaire   +2 more sources

Genetic determinants of apolipoprotein B-100 kinetics

Current Opinion in Lipidology, 2010
We review stable isotope tracer studies of apolipoprotein B-100 (apoB) kinetics concerning genetic polymorphisms and mutations that affect human lipoprotein metabolism.In obese men, the allelic combination of the apoB signal peptide, SP24, and cholesteryl ester transfer protein, CETP B1B1, is independently associated with lower VLDL apoB secretion ...
Theodore W K, Ng, Esther M M, Ooi, Gerald F, Watts, Dick C, Chan, P Hugh R, Barrett   +4 more
openaire   +2 more sources

Familial defective apolipoprotein B-100: A review

Journal of Clinical Lipidology, 2016
Familial defective apolipoprotein B-100 (FDB) is an autosomal dominant genetic disorder of lipid metabolism associated with hyperlipidemia and elevated risk for atherosclerosis. FDB is caused by mutations in APOB reducing the binding affinity between apolipoprotein B-100 and the low-density lipoprotein receptor.
Lars H. Andersen, André R. Miserez, Zahid Ahmad, Rolf L. Andersen   +3 more
openaire   +3 more sources

Degradation of apolipoprotein B-100 in human chylomicrons

Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988
The purpose of this study was to investigate the molecular forms of apolipoprotein B (ApoB) in human chylomicrons under well-preserved conditions. To this end, plasma and serum were collected from the same normal subjects after ingestion of a fatty meal.
D M, Lee, S, Singh
openaire   +2 more sources

Structural heterogeneity of apolipoprotein B‐100

The FEBS Journal
Cardiovascular disease is a major cause of human morbidity and mortality. Drug strategies for the prevention of the disease are largely centered on the interaction of low‐density lipoprotein receptor (LDLR) with the apolipoprotein B‐100 (apoB‐100) protein on low‐density lipoprotein (LDL). Recently, the structure of apoB‐100 on LDL was determined in the
Altaira D. Dearborn, Alan T. Remaley, Joseph Marcotrigiano   +2 more
openaire   +2 more sources

Familial defective apolipoprotein B-100 in hypercholesterolemic Chinese Canadians: identification of a unique haplotype of the apolipoprotein B-100 allele

Atherosclerosis, 1997
Familial defective apo B-100 (FDB) is an autosomal dominant condition resulting in hypercholesterolemia. It is generally observed in 1-6% of hypercholesterolemic subjects in Caucasian populations studied. There are, thus far, no reports characterizing the frequency and phenotype of FDB in a Chinese population. We report on the frequency of the FDB (Arg(
L O, Abdel-Wareth, S N, Pimstone, J P, Lagarde, A, Raisonnier, P, Benlian, H, Pritchard, M R, Hayden, J J, Frohlich   +7 more
openaire   +2 more sources

Lipoproteins Containing Apolipoprotein B-100 Are Secreted by the Heart

Trends in Cardiovascular Medicine, 1999
It generally is assumed that lipoproteins containing apolipoprotein B (apo B) are secreted only by the intestine and the liver. However, we recently demonstrated that the human apo-B gene also is expressed in the hearts of human apo-B transgenic mice and in human heart tissue.
M M, Véniant, L B, Nielsen, J, Borén, S G, Young   +3 more
openaire   +2 more sources